Gene polymorphism of transforming growth factor-β1 in Egyptian patients with type 2 diabetes and diabetic nephropathy

Acta Biochimica et Biophysica Sinica

Volumn 45, Issue 4, 2013, Pages 330-338

  El Sherbini, Sherif M ^a   Shahen, Samar M ^a   Mosaad, Youssef M ^b   Abdelgawad, Mohamed S ^b   Talaat, Roba M ^a  

^a MENOUFIA UNIVERSITY   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

DN ; DN+; Egyptian; Transforming growth factor 1; Type 2 diabetes

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ALLELE; ARTICLE; CODON; DIABETIC NEPHROPATHY; EGYPT; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HAPLOTYPE; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALLELES; CODON; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; EGYPT; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84879221253     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmt003     Document Type: Article

References (49)

1. Stumvoll M, Goldstein BJ and van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005, 365: 1333 - 1346.
2. Ahlqvist E, Ahluwalia TS and Groop L. Genetics of type 2 diabetes HMGA1, a novel locus for type 2 diabetes mellitus. Clin Chem 2011, 57: 241-254.
3. Fan XG, Liu WE, Li CZ, Wang ZC, Luo LX, Tan DM and Hu GL, et al. Circulating Th1 and Th2 cytokines in patients with hepatitis C virus infection mediators. Inflammation 1998, 7: 295-297.
4. Wilson AG, Symons JA, McDowell TL, McDevitt HO and Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997, 94: 3195-3199.
5. Ben-Ari Z, Mor E, Papo O, Kfir B, Sulkes J, Tambur AR and Tur-Kaspa R, et al. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol 2003, 98: 144-150.
6. Fernandez-Mestre MT, Gendzekhadze K, Rivas-Vetencourt P and Layrisse Z. IFN-αlpha-308 A allele: a possible severity risk factor of hemorrhagic manifestation in dengue fever patients. Tissue Antigens 2004, 64: 469-472.
7. Bendicho MT, Guedes JC, Silva NN, Santana GO, Dos Santos RR, Lyra AC and Lyra LG, et al. Polymorphism of cytokine genes (TGF-beta1; IFN-gamma; IL-6; IL-10; and TNFalpha) in patients with chronic pancreatitis. Pancreas 2005, 30: 333-336.
8. Bidwell J, Keen L, Gallacher G, Kimberly R, Huizinga T, McDermott MF and Oksenberg J, et al. Cytokine gene polymorphism in human disease: on-line databases. Genes Immunol 1999, 1: 3-19.
9. Lawrence DA. Transforming growth factor-beta: an overview. Kidney Int 1995, 49: S19-S23.
10. Fujii D, Brissenden JE, Derynck R and Francke U. Transforming growth factor beta gene maps to human chromosome 19 long arm and to mouse chromosome 7. Somat Cell Mol Genet 1986, 12: 281-288.
11. Watanabe Y, Kinoshita A, Yamada T, Ohta T, Kishino T, Matsumoto N and Ishikawa M, et al. A catalog of 106 single-nucleotide polymorphisms (SNPs) and 11 other types of variations in genes for transforming growth factor-b1 (TGF-b1) and its signaling pathway. J Hum Genet 2002, 47: 478-483.
12. Li X, Yue ZC, Zhang YY, Bai J, Meng XN, Geng JS and Fu SB. Elevated serum level and gene polymorphisms of TGF-b1 in gastric cancer. J Clin Lab Anal 2008, 22: 164-171.
13. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ and Hutchinson IV. Genotypic variation in the transforming growth factor-b1 gene: association with transforming growth factor-b1 production; fibrotic lung diseases; and graft fibrosis after lung transplantation. Transplantation 1998, 66: 1014-1020.
14. Blobe GC, Schiemann WP and Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 1998, 342: 1350-1358.
15. Ten DP and Hill CS. New insights into TGF-beta-Smad signaling. Trends Biochem Sci 2004, 29: 265-273.
16. Marks JB and Raskin P. Nephropathy and hypertension in diabetes. Med Clin North Am 1998, 82: 877-907.
17. Sharma K and Ziyadeh FN. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key medicator. Diabetes 1995, 44: 1139-1146.
18. American Diabetes Association (ADA). Standards of Medical Care in Diabetes - 2010. Diabetes Care 2010, 33: S11-S61.
19. Perrey C, Turner SJ, Pravica V, Howell WM and Hutchinson IV. ARMS-PCR methodologies to determine IL-10, IFN-αlpha, TNF-beta and TGF-beta 1 gene polymorphisms. Transpl Immunol 1999, 7: 127-128.
20. Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC and Carter ND, et al. Genetic control of circulating concentration of transforming growth factor beta 1. Hum Mol Genet 1999, 8: 93-97.
21. Shah R, Rahaman B, Hurley CK and Posch PE. Allelic diversity in the TGFB1 regulatory region: characterization of novel functional single nucleotide polymorphisms. Hum Genet 2006, 119: 61-74.
22. Buraczynska M, Baranowicz-Gaszczyk I, Borowicz E and Ksiazek A. TGF-beta1 and TSC-22 gene polymorphisms and susceptibility to microvascular complications in type 2 diabetes. Nephron Physiol 2007, 106: 69-75.
23. Wong TY, Poon P, Chow KM, Szeto CC, Cheung MK and Li PK. Association of transforming growth factor-beta (TGF-beta) T869C (Leu 10Pro) gene polymorphisms with type 2 diabetic nephropathy in Chinese. Kidney Int 2003, 63: 1831-1835.
24. Pickup JC, Chusney GC, Thomas SM and Burt D. Is type II diabetes mellitus a disease of the innate immune system?. Life Sci 2000, 67: 291-300.
25. Li MO, Wan YY, Sanjabi S, Robertson AKL and Flavell RA. Transforming growth factor-B regulation of immune respsonses. Ann Rev Immunol 2006, 24: 99-146.
26. Naiki Y, Michelsen KS, Zhang W, Chen S, Doherty TM and Arditi M. Transforming growth factor-B differentially inhibits MyD88-dependent, but not TRAM- and TRIF-dependent; lipopolysaccharide-induced TLR4 signaling. J Biol Chem 2005, 280: 5491-5495.
27. Herder C, Brunner EJ, Rathmann W, Strassburger K, Tabák AG, Schloot NC and Witte DR. Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II Study. Diabetes Care 2009, 32: 421-423.
28. Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B and Mandrup-Poulsen T, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007, 356: 1517-1526.
29. Wan YY and Flavell RA. 'Yin-Yang' functions of transforming growth factor-beta and T regulatory cells in immune regulation. Immunol Rev 2007, 220: 199-213.
30. Thorand B, Kolb H, Baumert J, Koenig W, Chambless L, Meisinger C and Illig T, et al. Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/ KORA Augsburg Study, 1984-2002. Diabetes 2005, 54: 2932-2938.
31. Miljkovic D, Cvetkovic I, Momcilovic M, Maksimovic-Ivanic D, Stosic-Grujicic S and Trajkovic V. Interleukin-17 stimulates inducible nitric oxide synthase-dependent toxicity in mouse beta cells. Cell Mol Life Sci 2005, 62: 2658-2668.
32. Johansson KA and Grapin-Botton A. Development and diseases of the pancreas. Clin Genet 2002, 62: 14-23.
33. Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, Kemp PR and Luben RN, et al. A transforming growth factor beta 1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 2003, 63: 2610-2615.
34. Border WA and Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994, 331: 1286-1292.
35. US Renal Data System (USRDS). Annual data report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institute of Health National Institute of Diabetes and Digestive and Kidney Disease; 2003.
36. Ziyadeh FN. Different roles for TGF-beta and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy. Diabetes Res Clin Pract 2008, 82: S38-S41.
37. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E and Border WA. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993, 90: 1814-1818.
38. Sharma K, Ziyadeh FN, Alzahabi B, McGowan TA, Kapoor S, Kurnik PB and Weisberg LS. Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 1997, 46: 854-859.
39. Hoffman BB, Sharma K, Zhu Y and Ziyadeh FN. Transcriptional activation of transforming growth factor-beta1 in mesangial cell culture by high glucose concentration. Kidney Int 1998, 54: 1107-1116.
40. Tsilibary EC. Microvasular basement membranes in diabetes mellitus. J Pathal 2003, 200: 537-546.
41. Kopp JB, Factor VM, Mozes M, Nagy P, Sanderson N, Bottinger EP and Klotman PE, et al. Transgenic mice with increased plasma levels of TGF-beta1 develop progressive renal disease. Lab Investig 1996, 74: 991-1003.
42. Valladares-Salgado A, Angeles-Martinez J, Rosas M, Garcia-Mena J, Utrera-Barillas D, Gomez-Diaz R and Escobedo-de la Penä J, et al. Association of polymorphisms within the transforming growth factor-beta1 gene with diabetic nephropathy and serum cholesterol and triglyceride concentrations. Nephrology (Carlton) 2010, 15: 644-648.
43. Ahluwalia TS, Khullar M, Ahuja M, Kohli HS, Bhansali A, Mohan V and Venkatesan R, et al. Common variants of inflammatory cytokine genes are associated with risk of nephropathy in type 2 diabetes among Asian Indians. PLoS One 2009, 4: e5168.
44. Akai Y, Sato H, Ozaki H, Iwano M, Dohi Y and Kanauchi M. Association of transforming growth factor-beta1 T29C polymorphism with the progression of diabetic nephropathy. Am J Kidney Dis 2001, 38: S182-S185.
45. Jia H, Yu L, Gao B and Ji Q. Association between the T869C polymorphism of transforming growth factor-beta1 and diabetic nephropathy: a meta-analysis. Endocrine 2011, 40: 372-378.
46. Sharma K and Ziyadeh FN. Renal hypertrophy is associated with upregulation of TGF-beta1 gene expression in diabetic BB rat and NOD mouse. Am J Physiol 1994, 267: F1094-F1101.
47. Idogun ES and Kasia BE. Assessment of microalbuminuria and glycated hemoglobin in type 2 diabetes mellitus complications. Asian Pacific J Trop Dis 2011, 203-205.
48. Roestenberg P. Diabetes nephropathy and the pathogenic role of growth factors (nephrological issues in Experimental Research.).org [Online]. Available from www.NIER (nephrological issues in Experimental Research.).org (2006) (22 January 2007, date last accessed).
49. Qian Y, Feldman E, Pennathur S, Kretzler M and Brosious FC. From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy. Diabetes 2008, 57: 1439-1445.